Thursday, December 16, 2021 1:58:44 PM
Dec. 16, 2021 12:58 PMBioNTech SE (BNTX)By: Dulan Lokuwithana, SA News Editor
BioNTech And Pfizer To Begin Clinical Trial For Covid-19 Vaccine
Thomas Lohnes/Getty Images News
While COVID-related revenue will remain as its key valuation driver, next year, investors of BioNTech (NASDAQ:BNTX) will start to see the company’s non-COVID pipeline, the analysts at Morgan Stanley argue, initiating its coverage on the stock with an Equal Weight rating.
“BioNTech is more than a COVID-19 mRNA company,” they added, citing its diverse pipeline targeted at oncology and infectious diseases including influenza, melanoma, and head/neck cancer.
As key drivers for its stock, the analysts led by Matthew Harrison term the impact of new variants, requirements for annual boosters, and the company’s efforts to compete with a pan respiratory vaccine. They also highlight a range of readouts scheduled for next year in its oncology pipeline.
However, comparing its market cap to those of Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and Vertex (NASDAQ:VRTX), the team also argues that the German biotech appears fairly valued despite having a single product with an uncertain long-term outlook. The price target of $294 per share implies a premium of ~2.4% to the last close.
As shown in the diagram below, the Bullish recommendations on BioNTech (BNTX) have gradually increased on Wall Street over the past six months.
BNTX $$$$
DO always your own DD , before you invest in any stock !
My opinion is always only my opinion !
Good Luck to all !
Recent BNTX News
- Apple Pre-Market Drop Due to Antitrust Threats, Surprising Profit Boosts Micron Shares, and Latest Market Updates • IH Market News • 03/21/2024 11:17:26 AM
- U.S. Index Futures Trade Sideways Amid Anticipation of Fed’s Policy Update; Oil Prices Dip • IH Market News • 03/20/2024 11:17:32 AM
- BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update • GlobeNewswire Inc. • 03/20/2024 10:15:00 AM
- BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer • GlobeNewswire Inc. • 03/20/2024 10:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/11/2024 01:04:00 PM
- BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024 • GlobeNewswire Inc. • 03/11/2024 11:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 12, 2024 in BioNTech Lawsuit - BNTX • PR Newswire (US) • 03/11/2024 10:25:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/07/2024 01:41:50 PM
- BioNTech Announces Planned Retirement of Sean Marett • GlobeNewswire Inc. • 03/07/2024 11:45:00 AM
- BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024 • GlobeNewswire Inc. • 03/06/2024 11:45:00 AM
- The Gross Law Firm Reminds BioNTech SE Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 12, 2024 - BNTX • PR Newswire (US) • 03/05/2024 10:45:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/28/2024 11:26:07 PM
- Shareholders that lost money on BioNTech SE(BNTX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 02/26/2024 10:45:00 AM
- BioNTech SE Sued for Securities Law Violations - Contact The Gross Law Firm Before March 12, 2024 to Discuss Your Rights - BNTX • PR Newswire (US) • 02/22/2024 10:45:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/15/2024 09:10:24 PM
- Shareholders that lost money on BioNTech SE(BNTX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 02/15/2024 10:00:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 12:26:25 PM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of BioNTech SE(BNTX) Shareholders • PR Newswire (US) • 02/09/2024 10:45:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/08/2024 11:08:22 AM
- BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs • GlobeNewswire Inc. • 02/08/2024 10:45:00 AM
- BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs • GlobeNewswire Inc. • 02/08/2024 10:45:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/07/2024 10:03:50 PM
- The Gross Law Firm Notifies Shareholders of BioNTech SE of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 12, 2024 - (NASDAQ: BNTX) • PR Newswire (US) • 02/02/2024 10:45:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/31/2024 12:47:45 PM
- BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305 • GlobeNewswire Inc. • 01/31/2024 11:45:00 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM